Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

Three of Australia’s largest healthcare shares have continued their fall in 2026: 

• Pro Medicus Ltd (ASX: PME) shares have dropped 38% year to date
• CSL Ltd (ASX: CSL) shares are down 19% 
• ResMed Inc (ASX: RMD) shares have fallen nearly 10%. 

At what point do blue-chip stocks become too cheap to ignore?

Let’s find out.

Why are healthcare stocks in a free fall?

It has been a rough stretch for ASX healthcare stocks like ResMed shares in the last year. 

The S&P/ASX 200 Health Care (ASX:XHJ) index is down 28% in that span. 

For comparison, the S&P/ASX 200 Index (ASX: XJO) is up nearly 16% in that same period. 

There have been several headwinds weighing on sentiment in this period: 

• Many healthcare stocks are growth companies. When interest rates rise, the future earnings that growth stocks are valued on get discounted more heavily, reducing their present value
• Tariff pressure have also hurt ASX healthcare stocks
• Many ASX healthcare giants earn significant revenues offshore (particularly in the US), so a stronger US dollar hurts the translation of those earnings back into Australian dollars.

It’s important to note that these headwinds are not guaranteed to subside in the short-term. 

But with a long-term lens, the current stock price for healthcare giants could be a value play. 

Here’s what experts are saying. 

Pro Medicus Ltd (ASX: PME)

Pro Medicus is a provider of medical imaging technology globally. The company is recognised as a leading supplier of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions for medical practices and hospitals.

It remains down almost 60% from to 52-week highs, closing yesterday at $137.42. 

Pro Medicus shares have a strong chance of rebounding based on analysts forecasts via TradingView. 

The average price target of 14 analysts sits at $199.03 per share. 

That’s 61% higher than current levels. 

CSL Ltd (ASX: CSL)

CSL is Australia’s largest healthcare stock. 

It is a biotechnology company that develops and delivers biotherapies and vaccines. 

Its share price is down 42% over the last year, and now could simply be too cheap to ignore. 

At the time of writing, shares in CSL are trading for approximately $139.44. 

This is almost 63% below the average fair price estimate from 16 analysts. 

ResMed Inc (ASX: RMD)

Finally, ResMed shares are another blue-chip healthcare stock worth buying low. 

The company is a global leader in sleep technology.

Its share price is down roughly 10% this year, trading today for approximately $32.70. 

The team at Ord Minnett recently placed a $41.40 price target on ResMed shares. 

If it reached this price, it would represent a 26% rise. 

The post Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares? appeared first on The Motley Fool Australia.

More reading

• How much would $10,000 become if CSL shares returned to their record high?
• One ASX share to double, one yielding 11% — ASX picks for April
• 5 ASX growth shares to buy and hold for 5 years
• 10 years to retirement? Here’s how to build a solid income
• How I would build the ultimate beginner portfolio with $10,000

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.